BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 38714686)

  • 1. CAR-T overdrive: harnessing inosine for metabolic rewiring and stemness induction.
    Farrera-Sal M; Schmueck-Henneresse M
    Signal Transduct Target Ther; 2024 May; 9(1):120. PubMed ID: 38714686
    [No Abstract]   [Full Text] [Related]  

  • 2. Chimeric antigen receptor T-cell therapy for cancer: a basic research-oriented perspective.
    Han C; Kwon BS
    Immunotherapy; 2018 Mar; 10(3):221-234. PubMed ID: 29370727
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Manufacturing Chimeric Antigen Receptor (CAR) T Cells for Adoptive Immunotherapy.
    Ghassemi S; Milone MC
    J Vis Exp; 2019 Dec; (154):. PubMed ID: 31904011
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Application of mRNA nano-delivery system in CAR-T tumor immunotherapy].
    Zeng Y; Wei S; Sun J; Xu N
    Sheng Wu Gong Cheng Xue Bao; 2024 May; 40(5):1338-1351. PubMed ID: 38783801
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Construction of a chimeric antigen receptor bearing a nanobody against prostate a specific membrane antigen in prostate cancer.
    Hassani M; Hajari Taheri F; Sharifzadeh Z; Arashkia A; Hadjati J; van Weerden WM; Modarressi MH; Abolhassani M
    J Cell Biochem; 2019 Jun; 120(6):10787-10795. PubMed ID: 30672018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAR-T therapy: Prospects in targeting cancer stem cells.
    Cui X; Liu R; Duan L; Cao D; Zhang Q; Zhang A
    J Cell Mol Med; 2021 Nov; 25(21):9891-9904. PubMed ID: 34585512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CAR T cell therapies for patients with multiple myeloma.
    Mikkilineni L; Kochenderfer JN
    Nat Rev Clin Oncol; 2021 Feb; 18(2):71-84. PubMed ID: 32978608
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CAR T cells for solid tumors - developments to watch in 2023.
    Trefny MP; Kobold S
    Expert Opin Biol Ther; 2024 Apr; 24(4):207-211. PubMed ID: 38526025
    [No Abstract]   [Full Text] [Related]  

  • 9. Generation of CAR-T Cells for Cancer Immunotherapy.
    Xu Q; Harto H; Berahovich R; Xu S; Zhou H; Golubovskaya V; Wu L
    Methods Mol Biol; 2019; 1884():349-360. PubMed ID: 30465215
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Senolytic CAR T Cells in Solid Tumors and Age-Related Pathologies.
    Feucht J; Abou-El-Enein M
    Mol Ther; 2020 Oct; 28(10):2108-2110. PubMed ID: 32841587
    [No Abstract]   [Full Text] [Related]  

  • 11. CD70 CAR T cells in AML: Form follows function.
    Mirazee J; Shah NN
    Cell Rep Med; 2022 May; 3(5):100639. PubMed ID: 35584621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cells expressing NKG2D chimeric antigen receptors efficiently eliminate glioblastoma and cancer stem cells.
    Yang D; Sun B; Dai H; Li W; Shi L; Zhang P; Li S; Zhao X
    J Immunother Cancer; 2019 Jul; 7(1):171. PubMed ID: 31288857
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CAR T-cells for relapsed B-cell ALL in adults.
    Gilbert JA
    Lancet Oncol; 2018 Mar; 19(3):e143. PubMed ID: 29429915
    [No Abstract]   [Full Text] [Related]  

  • 14. CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.
    Kuhn NF; Purdon TJ; van Leeuwen DG; Lopez AV; Curran KJ; Daniyan AF; Brentjens RJ
    Cancer Cell; 2019 Mar; 35(3):473-488.e6. PubMed ID: 30889381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A metabolic switch to memory CAR T cells: Implications for cancer treatment.
    Rostamian H; Fallah-Mehrjardi K; Khakpoor-Koosheh M; Pawelek JM; Hadjati J; Brown CE; Mirzaei HR
    Cancer Lett; 2021 Mar; 500():107-118. PubMed ID: 33290868
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic engineering of T cells with chimeric antigen receptors for hematological malignancy immunotherapy.
    Ti D; Niu Y; Wu Z; Fu X; Han W
    Sci China Life Sci; 2018 Nov; 61(11):1320-1332. PubMed ID: 30414005
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of Cell and Genome Modification Technologies to Generate Improved "Off-the-Shelf" CAR T and CAR NK Cells.
    Morgan MA; Büning H; Sauer M; Schambach A
    Front Immunol; 2020; 11():1965. PubMed ID: 32903482
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Chimeric Antigen Receptor T-Cells for the Treatment of B-Cell Acute Lymphoblastic Leukemia.
    Tomuleasa C; Fuji S; Berce C; Onaciu A; Chira S; Petrushev B; Micu WT; Moisoiu V; Osan C; Constantinescu C; Pasca S; Jurj A; Pop L; Berindan-Neagoe I; Dima D; Kitano S
    Front Immunol; 2018; 9():239. PubMed ID: 29515572
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CAR-T cells: the long and winding road to solid tumors.
    D'Aloia MM; Zizzari IG; Sacchetti B; Pierelli L; Alimandi M
    Cell Death Dis; 2018 Feb; 9(3):282. PubMed ID: 29449531
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Advances in CAR T-Cell Therapy for Aggressive B-NHL.
    Riedell PA
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S94-S97. PubMed ID: 32862885
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.